Please ensure Javascript is enabled for purposes of website accessibility

Why Intersect ENT Stock Is Skyrocketing Today

By Keith Speights - Jul 8, 2020 at 11:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors reacted enthusiastically to a reported acquisition offer from Medtronic.

What happened

Shares of Intersect ENT (XENT) were skyrocketing 29.6% higher as of 11:13 a.m. EDT on Wednesday. The big jump came after Bloomberg reported that medical device giant Medtronic (MDT -0.14%) made an offer to acquire Intersect. 

So what

No terms of the potential acquisition were disclosed in the Bloomberg article. However, for any deal to be approved by Intersect's board and shareholders, Medtronic would likely have to offer a significant premium to Intersect's recent trading price.

Woman drawing big fish about to eat small fish

Image source: Getty Images.

Investors' excitement about a possible acquisition makes sense. Intersect's revenue fell in the first quarter from the prior-year period. This decline stemmed from hospitals delaying elective surgical procedures and from lower ENT (ear, nose, and throat) office visits because of the COVID-19 pandemic. As a result, Intersect lost more than half of its valuation earlier this year. The reported acquisition offer is the best news for Intersect in quite a while.

It also makes sense why Medtronic would be interested in Intersect ENT. The smaller company markets products for ear, nose, and throat conditions, which presents a new market opportunity for Medtronic. 

The price tag, whatever it might be, shouldn't be a problem for Medtronic, either. The company had more than $4 billion in cash as of April 24, 2020. Even after today's big gain, Intersect's market cap is only around $600 million. 

Now what

Keep in mind that the deal isn't done yet. Intersect's board of directors is reportedly reviewing Medtronic's offer with advisors. It's also possible that the transaction will fall through. Depending on what happens, Intersect's shares could rise even more -- or the healthcare stock could sink. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intersect ENT, Inc. Stock Quote
Intersect ENT, Inc.
XENT
Medtronic plc Stock Quote
Medtronic plc
MDT
$94.04 (-0.14%) $0.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.